JOHNSON & JOHNSON (JNJ)
Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE
$271.13
+3.34%
Investingg Score
67.3 / 100
Hold
Business overview
- Gross margin of 67.9% indicating strong profitability on products sold.
- Free cash flow margin of 20.9% reflecting efficient conversion of revenue into cash.
These strong margins demonstrate the company's ability to generate reliable cash flow and maintain core profitability.
Financial health
- Balance Sheet score of 46 indicating moderate underlying financial positioning.
- Market capitalization listed as 0 due to data limitations in the provided set.
While cash generation is solid, the overall financial health presents mixed signals requiring cautious monitoring.
- Gross Margin
- 67.9%
- Operating Margin
- Data unavailable
- Current Ratio
- 1.0x
- Debt / Equity
- 0.48
- Free Cash Flow (TTM)
- $19.7B
- Interest Coverage
- Data unavailable
Valuation
- P/E ratio, EV to EBITDA, and FCF yield are all marked as unavailable.
- Price-to-sales ratio is reported as 0 based on the dataset.
The absence of key valuation multiples introduces significant uncertainty when assessing the current share price attractiveness.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 0.0x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Data unavailability for critical valuation multiples like P/E and EV to EBITDA creates analytical uncertainty.
- A Balance Sheet score of 46 points to potential balance sheet vulnerabilities.
- A market capitalization value of 0 in the dataset limits complete size assessment.
Market cap $0 · data as of 2026-08-18
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze JNJ with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.